July 12, 2012 | Vol. 11 No. 136 | Full Issue in PDF Format
View the entire issue.
GlaxoSmithKline’s (GSK) investigational integrase inhibitor dolutegravir bested Gilead’s dominant HIV therapy Atripla in a late-stage trial, setting the drug up to compete with both Atripla and Gilead’s Quad, which is likely to get approval soon.
Eli Lilly’s schizophrenia candidate has failed in a Phase IIb trial but Lilly will continue with a second similar trial for the drug, it says.
An Ohio District Court ruling that the FDA can approve generics on a withdrawn brand product could spell bad news for brand drugmakers trying to ward off generic competition.
House Republicans, joined by a handful of Democrats, voted Wednesday to repeal the 2010 Affordable Care Act (ACA) — the 31st time the GOP has tried to take down or truncate the law, House Democrats said.
Exemplar Pharmaceuticals, a contract manufacturer of nasal sprays and other aerosol-based drugs, was handed a Form 483 for process control deficiencies tied to filling foul ups.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.